Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT05671887
Official study title

DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies

Study summary

This is a prospective observational registration trial for patients who undergo lung transplantation for the treatment of the select groups of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedDouble Lung Transplantation

The study team can explain what participation involves.

Who it may be forResistant or refractory

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 21, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Northwestern University

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Northwestern University
Interventions being studied
Procedure: Double Lung Transplantation
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Resistant or refractory→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Any patient who is undergoing double lung transplantation as part of the clinical program, consents for this prospective observational trial, and has one of the following conditions will be eligible.
  • Common Inclusion Criteria
  • Adults of Age ≦ 80
  • Resistant or refractory to or without available standard of care treatment options or experimental treatment options that are known to increase survival outcome
  • Patients without any extrapulmonary disease
  • Patients with good general health with an ability to withstand physiologic stressors and undergo psychosocial evaluation by the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) or other assessment tools
  • Patients to meet all other criteria for lung transplantation including insurance approval and United Network for Organ Sharing (UNOS) registration Inclusion Criteria for Cohort A
  • Histologically confirmed selected lung non-small cell lung cancer including but not limited to: o according to the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification \- Lepidic dominant pattern
  • Adenocarcinoma in situ
  • Minimally invasive adenocarcinoma
  • Non mucinous lepidic predominant invasive adenocarcinoma o based on 2015 World Health Organization (WHO) classification of lung tumors including \- Invasive mucinous adenocarcinoma
  • Mixed invasive mucinous and mucinous adenocarcinoma
  • Colloid adenocarcinoma
  • Enteric adenocarcinoma
  • Minimally invasive adenocarcinoma
  • Nonmucinous
  • Mucinous \- Preinvasive lesions
  • Atypical adenomatous hyperplasia
  • Adenocarcinoma in situ
  • Nonmucinous
  • Mucinous
  • based on the 2004 WHO classification of lung tumors including - Bronchioloalveolar carcinoma
  • Nonmucinous
  • Mucinous
  • Mixed nonmucinous and mucinous or indeterminate
  • Without any distant metastasis confirmed by standard staging work-up
  • Without brain metastasis confirmed by brain imaging
  • Without unidentified primary site of cancer Inclusion Criteria for Cohort B
  • Metastatic cancers to lung alone - including but not limited to germ cell tumors, head \& neck tumors, colorectal tumors, renal cell tumors, testicular cancer
  • Without any other distant metastasis confirmed by standard staging work-up Inclusion Criteria for Cohort C
  • Respiratory failure with a history of cancer in the last 5 years - including, but not limited to interstitial lung disease (ILD), pulmonary fibrosis (idiopathic or secondary), advanced chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, cystic fibrosis (CF), emphysema due to alpha-1 antitrypsin deficiency, and pulmonary arterial hypertension (PAH)
  • Without any other distant metastasis confirmed by standard staging work-up

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Thoracic Surgery, Canning Thoracic Institute (Northwestern Memorial Hospital)Chicago, Illinois

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 21, 2026. Always confirm current availability with the study team.

View original record ↗